Form 4: Warburg Pincus Sells $158.7M in Sotera Health Stock

Warburg Pincus and its affiliated entities sold 9.72 million shares of Sotera Health Co. common stock for approximately $158.7 million in a pre-planned transaction.

Summary

• Warburg Pincus & Co. and several affiliated entities, collectively identified as a Director and 10% Owner of Sotera Health Co. (SHC), reported a sale of common stock.
• On December 3, 2025, these entities disposed of 9,720,000 shares of Sotera Health Co. Common Stock.
• The shares were sold at a price of $16.33 per share, totaling approximately $158,703,600.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• Following this sale, the Warburg Pincus Entities beneficially own 34,102,952 shares of Sotera Health Co. Common Stock indirectly.
• The remaining beneficial ownership consists of 27,291,923 shares held by Bull Holdco L.P. and 6,811,029 shares held by Bull Co-Invest L.P.

Sentiment

Score: 4

Explanation: A large insider sale by a significant institutional investor and director, even if pre-planned under Rule 10b5-1, generally carries a negative sentiment for existing shareholders. It reduces insider alignment and can be interpreted as a lack of conviction or a strategic exit, potentially leading to downward pressure on the stock.

Negatives

• A significant reduction in ownership by a major institutional investor and director, Warburg Pincus, which could be perceived as a decrease in conviction or a strategic exit.
• The sale of 9.72 million shares represents a substantial divestment, potentially creating downward pressure on the stock price.

Risks

• Potential negative market perception due to a large insider sale, even if pre-planned, which could lead to a decline in investor confidence.
• Increased selling pressure on Sotera Health Co. shares as a result of the large block of shares entering the market.

Future Outlook

The filing does not provide specific forward-looking statements or guidance from Sotera Health Co. management, focusing solely on the insider transaction.

Management Comments

• Warburg Pincus Entities disclaim beneficial ownership with respect to any shares of Common Stock of the Issuer, except to the extent of their pecuniary interest in such shares.
• The Warburg Pincus Entities are considered directors-by-deputization solely for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.

Industry Context

This insider transaction is specific to Sotera Health Co. and Warburg Pincus's investment strategy, and the filing does not provide broader industry context or trends.

Corporate Governance

Related Party Transactions

• The sale of 9,720,000 shares of Common Stock by Warburg Pincus Entities, who are identified as a 10% owner and director-by-deputization, constitutes a related party transaction.

Stakeholder Impact

• Shareholders: May experience negative sentiment and potential downward pressure on share price due to the significant insider sale, even if pre-planned.
• Company Management: The reduction in a major investor's stake might prompt questions regarding long-term strategic alignment and investor confidence.

Key Dates

Recommendation

The substantial sale of shares by Warburg Pincus, a significant owner and director, indicates a reduction in their stake in Sotera Health. While executed under a Rule 10b5-1 plan, suggesting a pre-determined strategy rather than an immediate reaction to negative news, such a large insider sale can be interpreted by the market as a decrease in conviction or a strategic portfolio rebalancing. Investors should monitor future insider activity and company performance closely, maintaining a 'hold' position with increased scrutiny.

Keywords

Sotera Health, SHC, Warburg Pincus, Insider Sale, Form 4, Beneficial Ownership, Rule 10b5-1, Institutional Investor